Orlance Inc. Awarded Pivotal $3M NIH SBIR Grant for Advancing MACH-1™ Needle-Free, Powdered Universal Influenza Vaccine to the Clinic

SEATTLE, Nov. 28, 2023 /PRNewswire/ — Orlance, Inc., a Seattle biotech developing next-generation DNA and RNA vaccines and therapeutics, has been awarded a three-year $3M National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant to advance its…

Click here to view original post